Opioid Use Disorder (OUD) Global Market Report 2024

The opioid use disorder (oud) market size has grown rapidly in recent years. It will grow from $3.53 billion in 2023 to $3.93 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historical period can be attributed to several factors, including an increase in prescription rates for opioid medications, evolving pain management practices, the impact of drug marketing, and the stigmatization associated with addiction. These factors collectively contributed to the patterns and challenges related to opioid use and addiction during the specified historical timeframe.

The opioid use disorder (oud) market size is expected to see rapid growth in the next few years. It will grow to $6.04 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth in the forecast period can be attributed to several factors, including regulatory interventions aimed at addressing opioid-related issues, an increased focus on alternative pain management strategies, efforts to expand access to treatment, and various public health initiatives. Key trends expected during this period encompass technological innovations in treatment methods, a shift toward individualized treatment approaches, the implementation of integrated care models, the development of community-based support programs, and an emphasis on early intervention and prevention measures. These trends collectively reflect a comprehensive and evolving approach to tackling the challenges associated with opioid use and addiction.

The escalating number of opioid addiction cases is poised to drive the expansion of the opioid use disorder (OUD) market. Opioid addiction denotes a medical condition characterized by persistent and compulsive use of opioids, leading to adverse effects on the body. These substances often induce euphoria and pain relief, fostering tolerance over time, wherein higher doses are necessary to achieve the same effects, potentially resulting in opioid use disorder. For example, data from the Centers for Disease Control and Prevention in May 2022 revealed a 15% increase in opioid overdose deaths in the USA, rising from 70,029 in 2020 to 80,816 in 2021. Thus, the mounting occurrences of opioid addiction cases are fueling the growth of the opioid use disorder (OUD) market.

The upsurge in the prevalence of chronic diseases is anticipated to propel the expansion of the opioid use disorder (OUD) market. Chronic diseases persist for a year or longer, demanding continuous medical attention and often limiting daily activities. Many chronic conditions, such as severe pain associated with cancer, arthritis, or other long-term ailments, frequently necessitate the use of opioid medications for effective pain management. For instance, projections from the National Centre for Biotechnology Information (NCBI) in January 2023 estimated a staggering 99.5% increase by the year 2050 in the number of individuals aged 50 years and older afflicted with at least one chronic illness, rising from 71.522 million in 2020 to 142.66 million. Thus, the surge in chronic disease prevalence is a driving force behind the growth of the opioid use disorder (OUD) market.

Product innovation stands out as a significant and increasingly favored trend in the opioid use disorder (OUD) market. Major companies operating within this sector are actively engaged in developing innovative products to maintain their market standing. An illustrative instance occurred in May 2023 when the U.S. Food and Drug Administration, a federal agency in the United States, granted approval for Brixadi (buprenorphine) extended-release injection to address moderate to severe cases of opioid use disorder (OUD). Brixadi is available in two dosage forms such as a weekly injection designed for patients commencing treatment with a single dose of transmucosal buprenorphine or those presently using the medication, and a monthly version tailored for individuals already receiving this treatment.

Prominent entities in the opioid use disorder (OUD) market are focused on forging strategic alliances to bolster their market position. Strategic alliances, taking diverse forms, aim to yield mutual benefits and fortify the market positions of the participating companies. An exemplar of this strategy occurred in March 2023, as Harm Reduction Therapeutics, a non-profit pharmaceutical company based in the United States, partnered with Catalent, Inc., a company specializing in developing and delivering advanced treatments globally. Within this collaboration, Catalent, Inc. will undertake the manufacturing of RiVive (3.0 mg), a naloxone nasal spray intended for harm reduction therapy, facilitating emergency treatment for known or suspected opioid overdose cases. This alliance was driven by the urgent need to address the ongoing opioid epidemic on a national scale. The goal behind developing an over-the-counter naloxone solution is to significantly broaden access, making naloxone more readily available to save lives imperiled by opioid overdoses.

In March 2023, the US-based pharmaceutical company Indivior plc successfully completed the acquisition of Opiant Pharmaceuticals Inc. for a total of $145 million. This strategic move is poised to enhance Indivior's product portfolio in the addiction treatment sector, fortifying its position in the market. Opiant Pharmaceuticals Inc., the acquired entity, is also based in the United States and specializes in the development of pharmaceuticals targeted at addressing opioid overdose, acute cannabinoid overdose, and opioid use disorder.

Major companies operating in the opioid use disorder (oud) market report are Pfizer Inc., Novartis AG, AstraZeneca plc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Chiesi Pharmaceuticals S.p.A., Hikma Pharmaceuticals Plc., Mallinckrodt Pharmaceuticals, Indivior Plc., Knight Therapeutics Inc., Purdue Pharma L.P, Alkermes Inc., Collegium Pharmaceutical Inc., Vanda Pharmaceuticals Inc., Camurus AB, Tris Pharma Inc., Mylan NV., Orexo US Inc., Zogenix Inc., Rhodes Pharmaceuticals L.P., Omeros Corporation, Braeburn Pharmaceuticals Inc., Adapt Pharma Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., Insys Therapeutics Inc., MediciNova Inc., Cara Therapeutics Inc., AcelRx Pharmaceuticals Inc., KemPharm Inc.,


North America was the largest region in the opioid use disorder (OUD) market in 2023. The regions covered in the opioid use disorder (oud) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the opioid use disorder (oud) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary medications for treating opioid use disorder (OUD) include buprenorphine, naltrexone, and methadone. Buprenorphine, classified as an opioid, is utilized in the management of opioid use disorder to mitigate cravings and alleviate withdrawal symptoms associated with opioid dependence. This medication is administered through oral and parenteral routes and is applicable across various age groups, including those aged 19 to 40, 41 to 60, and 61 and over. Distribution channels for buprenorphine include hospital pharmacies, retail pharmacies and stores, as well as online pharmacies.

The opioid use disorder (OUD) research report is one of a series of new reports that provides opioid use disorder (OUD) market statistics, including the opioid use disorder (OUD) industry's global market size, regional shares, competitors with opioid use disorder (OUD) market share, detailed opioid use disorder (OUD) market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (OUD) industry. This opioid use disorder (OUD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.